Skip to main content
    I

    Iterum Therapeutics PLC (ITRM)

    Official site

    BIOTECHNOLOGY

    $0.03
    +0.00 (+0.00%)

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(17/29)
    Avg Surprise
    +13.15%
    Streak
    1 Q
    Last 12 of 33 reported quarters
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 25
    Reported Mar 12
    Not reported$0.01N/A-----
    Sep 25
    Reported Nov 14
    -$0.20-$0.21N/A+4.76%Beat1
    No revisions (30d)
    +16.7%
    Jun 25
    Reported Aug 5
    -$0.16-$0.11N/A-45.45%Miss0
    No revisions (30d)
    +46.7%
    Mar 25
    Reported May 13
    -$0.14-$0.14N/A0.00%In line0
    No revisions (30d)
    +69.6%
    Dec 24
    Reported Feb 7
    -$0.12-$0.24-$0.24 - -$0.24+50.00%Beat1
    1
    0
    30d
    +87.2%
    Sep 24
    Reported Nov 14
    -$0.24-$0.21-$0.21 - -$0.21-14.29%Miss1
    1
    0
    30d
    +20.0%
    Jun 24
    Reported Aug 14
    -$0.30-$0.45-$0.52 - -$0.38+33.33%Beat2
    No revisions (30d)
    +68.4%
    Mar 24
    Reported May 13
    -$0.46-$0.72-$0.88 - -$0.57+36.11%Beat2
    No revisions (30d)
    +20.7%
    Dec 23
    Reported Mar 28
    -$0.94-$0.93-$1.02 - -$0.85-1.08%Miss2
    No revisions (30d)
    -80.8%
    Sep 23
    Reported Nov 14
    -$0.30-$0.91N/A+67.03%Beat--+69.1%
    Jun 23
    Reported Aug 11
    -$0.95-$0.79N/A-20.25%Miss---58.3%
    Mar 23
    Reported May 12
    -$0.58-$1.18N/A+50.85%Beat0
    No revisions (30d)
    -93.3%

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROIC-92.54%
    Financial Health
    Debt/Equity-4.57xInterest Coverage-10.61x
    Current Ratio2.13xQuick Ratio1.96x
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    As of Nov 16, 2026, the 50-day average is below the 200-day average. The 14-day RSI is 25.8, below 30, the oversold line.

    Moving Averages

    SMA 10$0.03
    SMA 20$0.03
    SMA 50$0.03
    SMA 200$0.08
    EMA 10$0.03
    EMA 20$0.03
    EMA 50$0.03
    EMA 200$0.13

    MACD

    Line: N/ASignal: N/AHist: N/A

    ADX

    ADX: 61.3+DI: 10.4-DI: 43.2

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down100.0
    PSAR$0.03

    Bollinger Bands

    Upper Band$0.03
    Lower Band$0.03
    %B Position0%(Lower)
    Band Width0.50

    RSI (14-Day)

    Oversold
    25.8

    Momentum Oscillators

    Stoch %KN/A
    Stoch %DN/A
    Williams %RN/A
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)N/A
    MFI (14d)N/A

    Volatility Measures

    ATR (14d)N/A(0.0%)
    StdDev (20d)N/A
    Hist VolN/A

    Volume Flow

    VWAP$0.03
    OBV593.3M
    AD Line-397.9M
    CMF (20d)N/A

    Volume Metrics

    Avg Vol (20d)N/A
    Vol RatioN/A
    VWMA (20d)N/A

    Pivot Points

    R3$0.03
    R2$0.03
    R1$0.03
    Pivot Point$0.03
    S1$0.03
    S2$0.03
    S3$0.03

    Advanced Oscillators

    TSI-49.32
    Ultimate OscN/A
    KSTN/A

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about ITRM

    News

    No news available

    Company news will appear here when available

    ITRM Valuation

    ITRM Profitability: Margins, ROIC and FCF

    Iterum Therapeutics (ITRM) posts -92.5% ROIC.

    ROIC
    -92.5%
    ITRM financial statements

    Iterum Therapeutics Competitors

    Peers by sector and size for Iterum Therapeutics (ITRM) include Flora Growth, Mobile-health Network Solutions Class A Ordinary Shares and Kairos Pharma.

    Sector: Healthcare

    ITRM Earnings: Beat Rate

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    7.9%

    ITRM Earnings Call

    The latest ITRM earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    See insider activity

    Updated Mar 12, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.